Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Discovery Grants Program - Individual

McGill University

$37,000.00

Improving CRISPR HDR by protein engineering the monoavidin domain and using nanobodies

FY 2019-20

Summary
CRISPR/Cas9 is a novel approach that creates double strand breaks (DSB) at specific genomic locations, specified by short RNA guide sequences (sgRNA). DSB can be repaired by nonhomologous edge joining (NHEJ) or homology directed repeari (HDR). NHEJ generates deletions and insertions (indels) at the DSB, which turn the gene off (frameshift or nonsense mediated decay). When donor DNA is present, it can be used to fix the DSB without error this is the essence of HDR. An external donor allows precise gene modifications and specific mutations. ***Unfortunately, when using Cas9, the major repair pathway is NHEJ and the number of cells that have undergone HDR can be quite low . Hence, isolated of cell clones with a desired engineered change resulting from HDR is time consuming, labor intensive, and low efficiency of***HDR means edited clones are scarce. This problem is a current bottleneck to high throughput implementation of HDR to establishing genotype phenotype relationships.***Our recently submitted work (CRISPR Journal) has described a method for increasing HDR rates without interventions. We have achieved success rates of up to 90% using Cas9 modified to contain monoavidin and bind to biotinylated dDNA. This new method allows creating and identifying a mutation within days, making feasible the idea of targeting multiple genes in a given population of cells. This has also been***proven beneficial in making transgenic animals.***Receptor-mediated transfection offers an attractive means to achieve preferential accumulation and therefore an increased efficacy of a therapeutic entity. Recently, small molecule ligands and aptamers have been coupled to the Cas9 protein or a Cas9 containing nanoparticle, respectively, for receptor-mediated uptake into cells. We have shown proof of concept of cell-specific transfection and editing using antibodies, which is useful for limiting gene editing to desirable subpopulations.******Goal and Specific Aims.***Our objective is to develop a better method for Cas9 Homology Directed Repair. ***Aim 1 extending our HDR method to other proteins in the CRISPR family. A specific protein from the CRISPR family can cut the genome in specific locations with the appropriate target sequence. For example, Cas9 protein from the bacteria Strep pyogenes (SpCas9) can cut those specific sites in the genome which begin with GG. Sequences in the genome that do not comply with SpCas9 rules are very***hard to cut and edit with SpCas9. Other proteins, for example Cas9 or Cpf1 from other bacteria, can cut other specific locations in the genome. We are extending our method in order to fuse monoavidin to additional CRISPR proteins, including Cpf1, VQR SpCas9, xCas9, and High Fidelity Cas9 (which will result in lower off target effects).***Aim 2 Use CRISPR & receptor-mediated transfection to induce HDR in specific cells***We will investigate the ability of inducing HDR in specific cells via a Cas9-heavy chain antibody conjugate
Program
Discovery Grants Program - Individual
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
RGPIN-2019-05271
Name nom
Akavia, UriDavid
Department département
Biochemistry
Organization id
61
Institution établissement
McGill University
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2019
Competition year année de concours
2019
Award amount
37000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
DISCOVERY RESEARCH
Group fr
RECHERCHE AXÉE SUR LA DÉCOUVERTE
Committee code
1501
Committee name en
Genes, Cells and Molecules
Committee name fr
Gènes, cellules et molécules
Area of application code
9999
Area of application group en
Not available
Area of application group fr
Non disponible
Area of application en
Not available
Area of application fr
Non disponible
Research subject code
5403
Research subject group en
Biochemistry
Research subject group fr
Biochimie
Research subject en
Proteins and peptides, amino acids
Research subject fr
Protéines et peptides, acides aminés
Installment
NA
Partie
0
Nb partie
NA
Application title
Improving CRISPR HDR by protein engineering the monoavidin domain and using nanobodies
Keyword
NSERC
Application summary
CRISPR/Cas9 is a novel approach that creates double strand breaks (DSB) at specific genomic locations, specified by short RNA guide sequences (sgRNA). DSB can be repaired by nonhomologous edge joining (NHEJ) or homology directed repeari (HDR). NHEJ generates deletions and insertions (indels) at the DSB, which turn the gene off (frameshift or nonsense mediated decay). When donor DNA is present, it can be used to fix the DSB without error this is the essence of HDR. An external donor allows precise gene modifications and specific mutations. ***Unfortunately, when using Cas9, the major repair pathway is NHEJ and the number of cells that have undergone HDR can be quite low . Hence, isolated of cell clones with a desired engineered change resulting from HDR is time consuming, labor intensive, and low efficiency of***HDR means edited clones are scarce. This problem is a current bottleneck to high throughput implementation of HDR to establishing genotype phenotype relationships.***Our recently submitted work (CRISPR Journal) has described a method for increasing HDR rates without interventions. We have achieved success rates of up to 90% using Cas9 modified to contain monoavidin and bind to biotinylated dDNA. This new method allows creating and identifying a mutation within days, making feasible the idea of targeting multiple genes in a given population of cells. This has also been***proven beneficial in making transgenic animals.***Receptor-mediated transfection offers an attractive means to achieve preferential accumulation and therefore an increased efficacy of a therapeutic entity. Recently, small molecule ligands and aptamers have been coupled to the Cas9 protein or a Cas9 containing nanoparticle, respectively, for receptor-mediated uptake into cells. We have shown proof of concept of cell-specific transfection and editing using antibodies, which is useful for limiting gene editing to desirable subpopulations.******Goal and Specific Aims.***Our objective is to develop a better method for Cas9 Homology Directed Repair. ***Aim 1 extending our HDR method to other proteins in the CRISPR family. A specific protein from the CRISPR family can cut the genome in specific locations with the appropriate target sequence. For example, Cas9 protein from the bacteria Strep pyogenes (SpCas9) can cut those specific sites in the genome which begin with GG. Sequences in the genome that do not comply with SpCas9 rules are very***hard to cut and edit with SpCas9. Other proteins, for example Cas9 or Cpf1 from other bacteria, can cut other specific locations in the genome. We are extending our method in order to fuse monoavidin to additional CRISPR proteins, including Cpf1, VQR SpCas9, xCas9, and High Fidelity Cas9 (which will result in lower off target effects).***Aim 2 Use CRISPR & receptor-mediated transfection to induce HDR in specific cells***We will investigate the ability of inducing HDR in specific cells via a Cas9-heavy chain antibody conjugate